ChemoTech reports Q2 2026 interim results
Net sales for Q2 were 3,292 KSEK and 6,090 KSEK for H1. Net loss after financial items was 4,195 KSEK for H1.
See the latest news and media coverage for ChemoTech. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical technology company developing human and veterinary cancer treatments
chemotech.seLast updated
In short: ChemoTech reported record growth in 2025, driven by its Animal Care division, and took steps to restructure and raise capital for expansion.
Net sales for Q2 were 3,292 KSEK and 6,090 KSEK for H1. Net loss after financial items was 4,195 KSEK for H1.
The company expands into veterinary and human medicine consulting, launching a new website and ticker NEEMS on July 13, 2026.
The company issued 761,191 new shares for approximately SEK 2.55 million through a set-off of claims against existing shareholders and board members to decrease financial liabilities.
Net sales reach 2,798 KSEK, up from 2,472 KSEK. Strongest Q1 in history with progress in Animal Care and India approval.
The report is attached to this press release and can also be downloaded from the company's website January - March 2026 Net sales amounted to...
NOT FOR DISCLOSURE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN...
At close: July 25 at 8:21:31 a.m. GMT+2...
This financing round was specifically structured as a win-win for both existing shareholders and the new investors. The proceeds will support ChemoTech's continued commercial growth...
Track ChemoTech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.